Partnering

Simris Biologics collaborates with leading academic and clinical institutions, contract development and manufacturing organisations (CDMO), chemicals companies and pharmaceutical companies worldwide. Collaboration agreements and license agreements play a central role in the Company’s commercial strategy.

Within collaboration agreements Simris Biologics generates revenue for R&D services and materials provided to a partner developing a product. This could be a chemicals company looking to develop a new pesticide, a cosmetics brand seeking novel natural compounds with anti-aging properties or pharmaceutical companies aiming to develop a new Antibody Drug Conjugate (ADC) to treat cancer patients. Further revenue from the collaboration is generated as a project reaches key development milestones, gains regulatory approval in given territories and for products that reach commercial use, royalties on sales throughout the life of our patents.

License agreements provide a partner, such as a pharmaceutical company, the right to reserve a novel, natural biologic towards a specific target for an agreed length of time.